Recap: Clean Energy Fuels Q1 Earnings
Clean Energy Fuels (NASDAQ:CLNE) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:10 PM. Here’s…
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell
• Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
Tourmaline And Clean Energy Announce $70M Joint Development Agreement To Build CNG Stations In Western Canada
Investment will establish a commercial fueling network for heavy-duty natural gas trucks across Western Canada
CALGARY, AB, April 18, 2023 /CNW/ - Tourmaline Oil Corp. (TSX:TOU)
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Clean Energy To Provide 86M Gallons Of RNG To San Diego MTS ; Terms Not Disclosed
Clean Energy Fuels Corp. (NASDAQ: CLNE) has been awarded a contract by San Diego Metropolitan Transit System (MTS), to provide an expected 86 million gallons of renewable natural gas (RNG) to operate its bus fleet.
Clean Energy Fuels’ Debt Overview
Over the past three months, shares of Clean Energy Fuels Inc. (NASDAQ:CLNE) moved lower by 8.24%. Before having a look at the importance of debt, let's look at how much debt Clean Energy Fuels has.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today
Clean Energy Fuels (NASDAQ:CLNE) has outperformed the market over the past 5 years by 11.98% on an annualized basis producing an average annual return of 19.82%. Currently, Clean Energy Fuels has a market capitalization of $1.29 billion.
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers
Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.